Skip to main content

Enhertu Disease Interactions

There are 3 disease interactions with Enhertu (fam-trastuzumab deruxtecan).

Moderate

Fam-trastuzumab deruxtecan (applies to Enhertu) cardiac disease

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Heart Disease

Patients treated with fam-trastuzumab deruxtecan may be at increased risk of developing left ventricular dysfunction. Treatment with fam-trastuzumab deruxtecan has not been studied in patients with a history of clinically significant cardiac disease or LVEF less than 50% prior to initiation of treatment. Assess LVEF prior to initiation of treatment and at regular intervals during treatment as clinically indicated. Manage LVEF decrease through treatment interruption. Permanently discontinue fam-trastuzumab deruxtecan if LVEF of less than 40% or absolute decrease from baseline of greater than 20% is confirmed. Treatment should be permanently discontinued in patients with symptomatic congestive heart failure (CHF).

References

  1. "Product Information. Enhertu (fam-trastuzumab deruxtecan)." Daiichi Sankyo, Inc. (2020):
Moderate

Fam-trastuzumab deruxtecan (applies to Enhertu) hepatic impairment

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Liver Disease

Fam-trastuzumab deruxtecan has not been studied in patients with severe hepatic impairment (total bilirubin >3 to 10 times ULN and any AST). No dose adjustment is required in patients with mild (total bilirubin =ULN and any AST >ULN or total bilirubin >1 to 1.5 times ULN and any AST) or moderate (total bilirubin >1.5 to 3 times ULN and any AST) hepatic impairment. However, closely monitor patients with moderate hepatic impairment, due to potentially increased exposure, and possible increase of related toxicities.

References

  1. "Product Information. Enhertu (fam-trastuzumab deruxtecan)." Daiichi Sankyo, Inc. (2020):
Moderate

Fam-trastuzumab deruxtecan (applies to Enhertu) severe renal impairment

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Renal Dysfunction

Fam-trastuzumab deruxtecan has not been studied in patients with severe renal impairment. Caution is advised if used in these patients. No dose adjustment is required in patients with mild (creatinine clearance (CrCl) =60 and <90 mL/min) or moderate (CrCl =30 and <60 mL/min) renal impairment.

References

  1. "Product Information. Enhertu (fam-trastuzumab deruxtecan)." Daiichi Sankyo, Inc. (2020):

Enhertu drug interactions

There are 163 drug interactions with Enhertu (fam-trastuzumab deruxtecan).


Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.